Cystic Fibrosis Foundation expands partnership with Pfizer

11/20/2012 | Genetic Engineering & Biotechnology News

The Cystic Fibrosis Foundation committed up to $58 million over six years in a project with Pfizer to develop drugs targeting the Delta F508 genetic mutation associated with the disease. The CFF retains rights to any drug candidate Pfizer discovers but chooses not to develop.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC